Iniciar sesión Regístrese gratis

Hancock Jaffe Laboratories Inc Rentabilidad sobre recursos propios

¿Qué es el Rentabilidad sobre recursos propios de Hancock Jaffe Laboratories Inc?

El Rentabilidad sobre recursos propios de Hancock Jaffe Laboratories Inc es -55.76%

¿Cuál es la definición de Rentabilidad sobre recursos propios?



El rendimiento del capital es una medida de la rentabilidad de una empresa en relación con el valor contable del capital contable. Se calcula dividiendo los ingresos netos del año fiscal por el capital contable total.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Rentabilidad sobre recursos propios de compañías en Sector Health Care en NASDAQ en comparadas con Hancock Jaffe Laboratories Inc

¿Qué hace Hancock Jaffe Laboratories Inc?

Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.

Empresas con rentabilidad sobre recursos propios similar a Hancock Jaffe Laboratories Inc